Monopar Therapeutics, has seen a surge in its stock after announcing positive data from its Phase 1 study of the drug MNPR-101-Zr.
This news has excited investors and biotechnology enthusiasts who view Monopar Therapeutics as a promising and rapidly growing company. Based…